Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Stevens

Orthopaedic Surgery Bountiful, UT Medical Doctor

NPI 1902941479 CMS profile 503274

1551 Renaissance Towne Dr, Ste. 400, Bountiful, UT 84010

Open in the dashboard

General payments

$107,951

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Stevens of Bountiful, UT is reported in the CMS Open Payments database as having received $107,951 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,714 29
2024 General $19,293 32
2023 General $40,881 47
2022 General $2,107 16
2021 General $1,663 21
2020 General $1,561 18
2019 General $3,730 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Stevens
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to David Stevens were reported at $38,714. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year David Stevens Orthopaedic Surgery median Middle half National median
2019 $3,730 $644 $140–$2,844 $163
2020 $1,561 $312 $75–$1,860 $114
2021 $1,663 $520 $117–$2,495 $132
2022 $2,107 $598 $128–$2,731 $149
2023 $40,881 $461 $128–$2,264 $160
2024 $19,293 $497 $134–$2,475 $164
2025 $38,714 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Highridge Medical LLC $57,476 44 payments
  2. Zimvie Inc. $39,015 35 payments
  3. Globus Medical, Inc. $4,098 17 payments
  4. Zimmer Biomet Holdings, Inc. $2,156 19 payments
  5. NuVasive, Inc. $1,622 11 payments
  6. Nexxt Spine LLC $1,443 5 payments
  7. Centinel Spine, LLC $544 4 payments
  8. Nevro Corp. $280 9 payments
  9. Alafair Biosciences,Inc. $119 1 payment
  10. Teva Pharmaceuticals USA, Inc. $114 7 payments
  11. Other $1,083 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $80,550 25 payments
  2. Travel and Lodging $23,534 69 payments
  3. Food and Beverage $3,867 110 payments
Products named General payments · program years 2019–2025
  1. Vital $76,950 22 payments
  2. MOBI-C PLUG & FIT US $46,005 37 payments
  3. Mobi-C $38,928 34 payments
  4. ROI-A $36,450 8 payments
  5. ROI-C Spine $32,100 12 payments
  6. ZYSTON CURVE SPACER $25,500 4 payments
  7. ROI-C Spine $10,950 4 payments
  8. Zyston Straight Interbody Fusion System $10,950 4 payments
  9. Timberline $7,200 3 payments
  10. ProLift Expandable Interbody, 12mm x 28mm, Large 15 degree $4,200 1 payment
  11. Other $17,616 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

129

Median for Orthopedic Surgery: 203

Drug cost

$1,240

Median for Orthopedic Surgery: $1,433

Branded share of claims

65.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 20 $385
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $318
Ondansetron Odt Ondansetron Brand 46 $273
Methylprednisolone Generic 14 $139
Meloxicam Generic 11 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$167,117

Medicare's payments for the services billed

Medicare patients

120

Average age 74

Services billed

573

63 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Chronic kidney disease 32%
Depression 29%
Ischemic heart disease 25%
Heart failure 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record